Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Use of antihypertensive drugs by breast cancer status

From: Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women

Antihypertensive use Noncases Invasive In situ Invasiveness unknown p value
  48,792 1372 558 35  
All antihypertensive drugs
Never used 32,413 (66.4) 883 (64.3) 375 (67.2) 18 (51.4) 0.32
Former user 1204 (2.5) 33 (2.4) 13 (2.3) 1 (2.9)
Current user (<5 years) 7410 (15.2) 208 (15.1) 92 (16.5) 5 (14.3)
 (5–10 years) 4033 (8.3) 128 (9.3) 40 (7.2) 5 (14.3)
 (10+ years) 3732 (7.6) 120 (8.8) 38 (6.8) 6 (17.1)
Calcium channel blockers
Never used 45,089 (92.4) 1270 (92.6) 515 (92.3) 30 (85.7) 0.41
Former user 516 (1.1) 15 (1.1) 6 (1.1) 0 (0)
Current user (<5 years) 1804 (3.7) 44 (3.2) 21 (3.8) 1 (2.9)
 (5–10 years) 771 (1.6) 25 (1.8) 11 (2.0) 2 (5.7)
 (10+ years) 612 (1.3) 18 (1.3) 5 (0.9) 2 (5.7)
  1. Data presented as N (%)
  2. Distribution of the duration of use for any antihypertensive drug and for use of calcium channel blockers specifically. We calculated distribution of use for women who remained breast cancer free as well as those who developed breast cancer during the study follow-up period